Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
Type:
Application
Filed:
November 3, 2014
Publication date:
October 6, 2016
Inventors:
Guanglin Luo, Ling Chen, Gene M. Dubowchik, Swanee E. Jacutin-Porte, Prasanna Sivaprakasam, John E. Macor
Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising sing a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
March 4, 2016
Publication date:
October 6, 2016
Inventors:
Luke W. ASHCRAFT, Gustave BERGNES, Chihyuan CHUANG, Scott COLLIBEE, Pu-Ping LU, Bradley MORGAN, Alex MUCI, Xiangping QIAN, Jeffrey WARRINGTON, Zhe YANG
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-L-R1??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type:
Application
Filed:
April 1, 2016
Publication date:
October 6, 2016
Inventors:
Yao-Ling Qiu, Hui Cao, Wei Li, Jorden Kass, Xuri Gao, Xiaowen Peng, Meizhong Jin, Yat Sun Or
Abstract: A new process for the preparation of 5-fluoro-1H-pyrazoles of the general formula (I) as described herein comprising reacting an olefin with an hydrazine.
Abstract: The invention relates to pyrrole carboxamides bearing a fluoromethyl-moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Type:
Application
Filed:
June 17, 2016
Publication date:
October 6, 2016
Applicant:
GRÜNENTHAL GMBH
Inventors:
Melanie REICH, Stefan SCHUNK, Florian JAKOB, Henning STEINHAGEN, Nils DAMANN, Michael HAURAND, Marc ROGERS, Kathy MACKENZIE
Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
Type:
Application
Filed:
October 3, 2014
Publication date:
October 6, 2016
Inventors:
Keith Jones, Carl Rye, Nicola Chessum, Matthew Cheeseman, Adele E. Pasqua, Kurt G. Pike, Paul F. Faulder
Abstract: Compounds of the formulas: wherein: R1-R4, X1, Y1, and A are as defined herein are provided. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds are are useful for the treatment of a disease or disorder. In some embodiments, the disease or disorder is a proliferative disease such as cancer.
Abstract: Various embodiments disclosed relate to aziridinated triglycerides and polymers formed therefrom. In various embodiments, the present invention provides an aziridinated triglyceride having the structure described herein. In various embodiments, the present invention provides a method of making the aziridinated triglyceride, a method of crosslinking the aziridinated triglyceride to form a polymer, the polymer formed from the aziridinated triglyceride, a triglyceride with at least one pendent unsaturated group that can be used to form the aziridinated triglyceride, and a method of making the triglyceride having at least one pendent unsaturated group.
Type:
Application
Filed:
March 30, 2016
Publication date:
October 6, 2016
Inventors:
Ruqi Chen, Jason Shih-Hao Chen, Chaoqun Zhang, Michael Richard Kessler
Abstract: The invention generally relates to functional polymers and hydrogels. More particularly, the invention provides versatile monomers and polymers with well-defined functionalities, e.g., polycarbonates and poly(ester-carbonates), compositions thereof, and methods for making and using the same. The invention also provides cytocompatible poly(ethylene glycol)-co-polycarobonate hydrogels (e.g., crosslinked by copper-free, strain-promoted “click” chemistry).
Abstract: Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid of the formula (I), in particular amino acid salts such as the lysine salt and alkali metal salts such as the sodium salt and the potassium salt, processes for their preparation, medicaments comprising them and their use for controlling diseases.
Abstract: The present invention relates to difluoroethyl-oxazole substituted bridged spiro[2.4] heptane derivatives of formula (I), wherein the substituents at the piperidine ring are in trans-arrangement, their preparation and their use as pharmaceutically active compounds.
Abstract: The present invention provides compounds of Formula I and Formula II: or pharmaceutically acceptable salts or solvates thereof, as modulators of liver X receptors (LXRs), and compositions comprising any of such novel compounds and methods of use thereof. These compounds are useful as medicaments for treatment and/or prophylaxis for diseases or conditions related to activity of LXRs.
Type:
Application
Filed:
March 14, 2014
Publication date:
October 6, 2016
Applicants:
BRISTOL-MYERS SQUIBB COMPANY, EXELIXIS PATENT COMPANY LLC
Inventors:
Ellen K. Kick, Mandar Bodas, Raju Mohan, Brett B. Busch, Claudia Averbuj, Meriah Valente, Nicholas Wurtz, Prasanna Savanor Maddu Rao, Jeevanprakash Shetty, Alla Venu
Abstract: Iron overload is associated with pathological conditions such as oxidative stress, transfusional iron overload, thalassemia, primary hemochromatosis, secondary hemochromatosis, diabetes, liver disease, heart disease, cancer, radiation injury, neurological or neurodegenerative disorder, Friedreich's ataxia (FRDA), macular degeneration, closed head injury, irritable bowel disease, and reperfusion injury. The present invention provides methods and pharmaceutical compositions using desferrithiocin analogs of Formulae (A) and (J) for treating and/or preventing these pathological conditions, metal (e.g., iron, aluminum, a lanthanide, or an actinide (e.g., uranium)) overload conditions, and infectious diseases (e.g., malaria).
Type:
Application
Filed:
November 21, 2014
Publication date:
October 6, 2016
Applicant:
University of Florida Research Foundation, Inc.
Abstract: A method of treating or preventing fungal infection, which includes identifying a plant or animal having a fungal infection and administering an effective amount of an anti-fungal composition to the plant or animal to reduce the fungal infection. In a preferred form of the present invention, the antifungal composition is compound 13 or 33 and is combined with an azole compound, such as fluconazole.
Abstract: A compound represented by formula (I), or a pharmaceutically acceptable salt thereof: wherein R1 represents a group represented by the formula: a group represented by the formula: or a group represented by the formula: and R2 represents a 3-methyltetrahydro-2H-pyran-4-yl group or 4-methoxycyclohexyl group.
Abstract: Compounds having a structure of formula (I), including stereoisomers and pharmaceutically acceptable salts and solvates thereof: wherein R1 is as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, hyperkinetic disorders. Also disclosed are compositions containing these compounds in combination with a pharmaceutically acceptable carrier or diluent, as well as methods relating to the use in a subject in need thereof.
Abstract: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Type:
Application
Filed:
November 18, 2014
Publication date:
October 6, 2016
Inventors:
Kyle A. Emmitte, Craig W. Lindsley, P. Jeffrey Conn, Andrew S. Felts, Alice L. Rodriguez, Katrina A. Smith, Carrie K. Jones
Abstract: A series of substituted 5,6,7,8-tetrahydroimidazo[1,2-?]pyridine derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Type:
Application
Filed:
December 8, 2014
Publication date:
October 6, 2016
Inventors:
Sabine Defays, Jag Paul Heer, Victoria Elizabeth Jackson, James Andrew Johnson, Boris Kroeplien, John Robert Porter
Abstract: The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D]pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.
Type:
Application
Filed:
March 2, 2016
Publication date:
October 6, 2016
Inventors:
Evangelos Aktoudianakis, Gregory Chin, Richard L. Mackman, Samuel E. Metobo, Michael R. Mish, Hyung-jung Pyun, Jeff Zablocki
Abstract: The present invention relates to novel azaindole derivatives, and more particularly, to novel azaindole derivatives having histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof, the use thereof for the preparation of pharmaceutical compositions, pharmaceutical compositions containing the same, a method of treating disease using the pharmaceutical compositions, and methods for preparing the novel azaindole derivatives. The novel azaindole derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be used as agents for treating malignant tumor diseases, inflammatory diseases, rheumatoid arthritis, and neurodegenerative diseases.
Abstract: A process for preparation of compound of Formula (I) is disclosed. The application is also directed to polymorphic forms of the compound of formula (I).
Abstract: The present invention relates to compounds of the formula (I) wherein R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.
Type:
Application
Filed:
November 18, 2014
Publication date:
October 6, 2016
Inventors:
Daniel BUR, Corinna GRISOSTOMI, Oliver NAYLER, Lubos REMEN, Magali VERCAUTEREN, Richard WELFORD
Abstract: Provided in the present invention are a new method for preparing the crystalline forms of Temozolomide and three types of crystalline form of Temozolomide by the method. Said method comprises the following steps: a Temozolomide is dissolved into dimethyl sulphoxide, a second organic solvent is added for recrystallization to prepare the crystalline forms of Temozolomide, wherein the second organic solvent is an alcohol, a ketone, a halohydrocarbon or an ester.
Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.
Type:
Application
Filed:
November 11, 2014
Publication date:
October 6, 2016
Applicant:
THE BROAD INSTITUTE, INC.
Inventors:
EAMON COMER, NOBUTAKA KATO, CHRISTINA SCHERER, JESSICA BASTIEN, JEREMY DUVALL, TIMOTHY LEWIS, MORGANE SAYES, MATTHEW LEIGHTY, JUN PU, JENNIFER BEAUDOIN, BERTRAND BRAIBANT, BENITO MUNOZ
Abstract: The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates to the processes of preparation of these compounds, their intermediates, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune, or infectious diseases, disorders, or conditions in which protein kinase activity is implicated.
Abstract: The invention provides a mercaptoalkylglycoluril represented by the general formula (I): wherein R1 and R2 each independently represent a hydrogen atom, a lower alkyl group, or a phenyl group; R3, R4, and R5 each independently represent a hydrogen atom or a mercaptoalkyl group selected from a mercaptomethyl group, a 2-mercaptoethyl group, and a 3-mercaptopropyl group; and n is 0, 1, or 2. The invention further provides an epoxy resin composition comprising an epoxy resin and the mercaptoalkylglycoluril, and a method for producing a laminate or a multilayer printed circuit board using the same.
Abstract: A compound, or a pharmaceutically acceptable salt or solvate thereof, or conjugates thereof, selected from the group consisting of: wherein: (a) R10 is H, and R11 is OH, ORA, where RA is saturated C1-4 alkyl; (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is SOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation, or both M together are a divalent pharmaceutically acceptable cation.
Type:
Application
Filed:
June 14, 2016
Publication date:
October 6, 2016
Inventors:
Scott Jeffrey, Patrick Burke, Philip Wilson Howard
Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
Abstract: A method of making a mono-ether of an isohexide and art assemblage of novel. Song-chain isohexide mono-ethers are described. In particular, the method involves reacting an isohexide stereoisomer with a Bronsted base and an alkyl species. The resultant mono-ethers can serve as attractive antecedents or chemical scaffolds for making a derivative compound, such as various amphiphiles with potential uses as surfactants, dispersants, and lubricants, among others.
Abstract: The present invention discloses an anilino-substituted podophyllin derivative having antitumor activity, method for preparation thereof, and use thereof. By means of anilino reactions, the present invention introduces 4-chloro-3-methylaniline, 3-fluoro-4-methoxyaniline, 4,4?-diaminodiphenylmethane, o-anisidine, 4-chloro-2-aminoanisole, anthranilonitrile, 2,6-dichloro-4-aminophenol, N,N-dimethylamino meta-aniline, 2-ethyl-5-nitroaniline, 2 2?-diaminodiphenylsulfide, or 2-aminobenzotrifluoride into position 4 of the active C-ring of podophyllotoxin or 4?-demethylepipodophyllotoxin to obtain the aniline-substituted podophyllotoxin derivative shown in formula (V); by means of multi-pathway and multi-target effects on tumor cells, said derivative has significantly increased antitumor activity, and can be prepared as an antineoplastic drug and applied in clinical antitumor therapy.
Type:
Application
Filed:
September 5, 2014
Publication date:
October 6, 2016
Applicant:
HUBEI UNIVERSITY OF TECHNOLOGY
Inventors:
Yajie TANG, Yong YANG, Wei ZHAO, Hongmei LI
Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
Type:
Application
Filed:
June 7, 2016
Publication date:
October 6, 2016
Applicant:
AMGEN INC.
Inventors:
Matthew BIO, Sebastien CAILLE, Yuanqing FANG, Brian M. FOX, Brian S. LUCAS, Lawrence R. McGEE, Sean H. WIEDEMANN
Abstract: This invention provides maytansinoids having improved tumor inhibition activity, in particular, the present invention provides a method of treatment of cancer, in particular colon cancer, using maytansinoid compounds having two fused macrocyclic rings.
Type:
Application
Filed:
December 2, 2014
Publication date:
October 6, 2016
Inventors:
Hongjie ZHANG, Djaja D. SOEJARTO, Harry H.S. FONG
Abstract: A crystalline compound of formula (I): The compound of formula (I) is a ?-lactamase inhibitor and may be administered in combination with an antibacterial agent for prevention or treatment of bacterial infection.
Type:
Application
Filed:
November 7, 2014
Publication date:
October 6, 2016
Applicant:
Allecra Therapeutics SAS
Inventors:
Alessandro Lamonica, Marco Forzatti, Stefano Biondi
Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (Ia): including stereoisomers and pharmaceutically acceptable salts thereof, wherein A, A?, R1 and R2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Type:
Application
Filed:
April 1, 2016
Publication date:
October 6, 2016
Inventors:
Zhenhong R. Cai, Haolun Jin, Scott E. Lazerwith, Hyung-Jung Pyun
Abstract: The invention relates to silylated cyclic phosphonamides of the general formula (1) in which R1 represents an unsubstituted or fluoro-substituted alkyl group with 1-20 carbon atoms, R2, R3 each represent an unsubstituted or fluoro-substituted alkyl or alkyl group with 1-20 carbon atoms or a siloxy group with 1-20 silicon atoms, wherein two or three of the groups R1, R2, R3 can be connected to each other, R4 represents an unsubstituted or fluoro-substituted alkyl group with 1-20 carbon atoms, and n represents the values 1 or 2. The invention also relates to a method for producing the phosophonamides of the general formula (1), to diamines used during the production of the phosphonamides, to an electrolyte which contains the phosphonamides of the general formula (1), and to a lithium-ion battery which comprises a cathode, an anode, a separator, and the electrolyte.
Abstract: Articles and methods comprising persistent carbenes are provided, as well as related compositions. In some embodiments, a persistent carbene may be associated with a portion of a substrate (e.g., at least a portion of a surface on the substrate). In certain embodiments, the association of persistent carbene with the substrate may be used to affect certain properties of substrate (e.g., surface chemistry, stability). In some cases, a persistent carbene may be functionalized after association with a portion of a substrate. In some embodiments, a persistent carbene and at least one secondary compound may be associated with a portion of a substrate. Articles and methods of the present invention may be useful for applications involving electronics, sensing, microfabrication, nanotechnology, biomimetic, and drug delivery, amongst others.
Type:
Application
Filed:
June 15, 2016
Publication date:
October 6, 2016
Applicant:
Massachusetts Institute of Technology
Inventors:
Jeremiah A. Johnson, Aleksandr V. Zhukhovitskiy
Abstract: Laminated articles are provided including a porous fibrous nonwoven matrix and guanidine-functionalized metal silicate particles enmeshed within the porous fibrous nonwoven matrix. The laminated articles further include a first substrate and a second substrate sealed to the first substrate. Methods of making laminated articles and methods of using laminated articles are also provided.
Type:
Application
Filed:
December 12, 2014
Publication date:
October 6, 2016
Inventors:
Manjiri T. KSHIRSAGAR, Bong Y. YEOM, Timothy J. ROWELL, Satinder K. NAYAR
Abstract: A first compound having an atom in an oxidized state is reacted with a bis(trimethylsilyl) six-membered ring system or related compound to form a second compound having the atom in a reduced state relative to the first compound. The atom in an oxidized state is selected from the group consisting of Groups 2-12 of the Periodic Table, the lanthanides, As, Sb, Bi, Te, Si, Ge, Sn, and Al.
Abstract: The present invention relates to oligomeric organosilanes containing at least two different structural units within a molecule, selected from the structural units A, B, C and D joined in any desired linear, branched or cyclic arrangement, wherein at least one R, R1, R2, R3, R4 or R7 group is an alkyl polyether group —O—(R5—O)m—R6, to the preparation thereof and to the use thereof in rubber mixtures.
Type:
Application
Filed:
January 8, 2015
Publication date:
October 6, 2016
Applicant:
EVONIK DEGUSSA GMBH
Inventors:
Anke BLUME, Ralph MOSER, Sebastian ROSENSTINGL
Abstract: The invention relates to compounds having Formula (1): A-L-B or pharmaceutically acceptable salts thereof, wherein: A is a dicarbonyl sequestering moiety comprising a substituted aryl group or a substituted heteroaryl group; L is an optional linker moiety; and B is a mitochondrial targeting moiety. The invention also relates to pharmaceutical compositions containing such compounds and salts, and to the use of such compounds and salts for treating diabetes, preferably hyperglycemic diabetes. A mass spectrometry probe and to a method of labelling a biological molecule 1 for mass spectrometry detection are also described.
Type:
Application
Filed:
November 21, 2014
Publication date:
October 6, 2016
Inventors:
Michael Patrick MURPHY, Robin Andrew James SMITH, Richard Charles HARTLEY
Abstract: The invention describes membrane permeable creatine phosphate analog prodrugs, pharmaceutical compositions comprising membrane permeable creatine phosphate analog prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and genetic disorders affecting the creatine kinase system comprising administering creatine phosphate analog prodrugs or pharmaceutical compositions thereof. The invention also describes treating a genetic disease affecting the creatine kinase system, such as, for example, a creatine transporter disorder or a creatine synthesis disorder comprising administering creatine phosphate analog prodrugs or pharmaceutical compositions thereof.
Abstract: The present invention is to provide a hydrogen oxidation catalyst that does not contain platinum. Disclosed is a hydrogen oxidation catalyst that is a dinuclear transition metal complex having a chemical structure represented by the following general formula (1) or (2): wherein, in the general formulae (1) and (2), M1 and M2 are each independently Fe or Ru; Ar1 and Ar2 are each independently a cyclopentadienyl group or a pentamethylcyclopentadienyl group; Ar3 and Ar4 are each independently a divalent aromatic hydrocarbon group having 6 to 12 carbon atoms; and Ar5 is a monovalent aromatic hydrocarbon group having 6 to 12 carbon atoms, and in the general formula (2), R1 and R2 are each independently a hydrogen atom or a monovalent aliphatic hydrocarbon group having 1 to 3 carbon atoms.
Type:
Application
Filed:
October 14, 2014
Publication date:
October 6, 2016
Applicants:
THE UNIVERSITY OF TOKYO, TOYOTA JIDOSHA KABUSHIKI KAISHA
Abstract: A method for the isolation of lignin from a lignocellulosic biomass, comprising providing a lignocellulosic biomass; extracting sugar free lignin from the lignocellulosic biomass by contacting said biomass with an organic aqueous solution comprising water and at least one water miscible organic solvent, either discontinuously or continuously, whereby a biomass-solvent suspension is formed; separating the sugar free lignin solution from the biomass-solvent suspension to obtain a sugar free lignin solution and a cellulosic material enriched with lignin carbohydrate complexes and hemicellulose, and optionally isolating sugar free lignin from the sugar free lignin solution; extracting the lignin carbohydrate complexes from the cellulosic material enriched with lignin carbohydrate complexes and hemicellulose by contacting said cellulosic material with a liquid comprising at least water, whereby treated biomass suspension is formed; separating the lignin carbohydrate complexes solution from said treated biomass sus
Type:
Application
Filed:
November 19, 2014
Publication date:
October 6, 2016
Inventors:
Alexander Dybov, Bernd Mayer, Christopher Lucas Prince
Abstract: A method for the depolymerization of lignin includes the steps of: providing a black liquor obtained from the treatment of delignification of the biomass, concentrating the black liquor; and subjecting the concentrated black liquor to a hydrothermal treatment. An acid is added to the reaction mixture obtained in the previous step, and then the precipitate is separated from the liquid phase resulting in the previous step. Finally, the method includes the step of extracting, from the recovered liquid phase, the aromatic products of depolymerization of lignin, such as phenol, cresols, catechol and the derivatives thereof (3-methylcatechol, 4-methylcatechol and 4-ethylcatechol).
Type:
Application
Filed:
November 18, 2014
Publication date:
October 6, 2016
Applicant:
UNIVERSIDAD DEL PAIS VASCO-EUSKAL HERRIKO UNIBERTSITATEA (UPV/EHU)
Inventors:
Xabier ERDOCIA IRIARTE, Ma de los Ángeles CORCUERA MAESO, Jalel LABIDI BOUCHRIKA
Abstract: Compounds, compositions and methods are provided for use to inhibit infection by human immunodeficiency virus (HIV). More specifically, the present invention relates to glycomimetic compounds that inhibit HIV infection, and uses thereof.
Abstract: Fiber-containing composites are described that contain woven or non-woven fibers, and a cured binder formed from a binder composition that includes (1) a reducing sugar and (2) a crosslinking agent that includes a reaction product of a urea compound and a polycarbonyl compound. Exemplary reaction products for the crosslinking agent may include the reaction product of urea and an ?,?-bicarbonyl compound or an ?,?-bicarbonyl compound. Exemplary fiber-containing composites may include fiberglass insulation.
Abstract: The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is defined herein, which is a 2?-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.